- Home
- ITCI vs REG Comparison
ITCI vs REG Comparison
Compare ITCI & REG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITCI
- REG
- Stock Information
- Founded
- ITCI 2002
- REG 1963
- Country
- ITCI United States
- REG United States
- Employees
- ITCI N/A
- REG N/A
- Industry
- ITCI Biotechnology: Pharmaceutical Preparations
- REG Real Estate Investment Trusts
- Sector
- ITCI Health Care
- REG Real Estate
- Exchange
- ITCI Nasdaq
- REG Nasdaq
- Market Cap
- ITCI 13.5B
- REG 13.4B
- IPO Year
- ITCI N/A
- REG 1993
- Fundamental
- Price
- ITCI $131.36
- REG $70.39
- Analyst Decision
- ITCI Buy
- REG Buy
- Analyst Count
- ITCI 13
- REG 12
- Target Price
- ITCI $106.58
- REG $78.08
- AVG Volume (30 Days)
- ITCI 2.2M
- REG 1.1M
- Earning Date
- ITCI 05-06-2025
- REG 05-01-2025
- Dividend Yield
- ITCI N/A
- REG 3.99%
- EPS Growth
- ITCI N/A
- REG 3.43
- EPS
- ITCI N/A
- REG 2.11
- Revenue
- ITCI $680,852,000.00
- REG $1,503,291,000.00
- Revenue This Year
- ITCI $40.64
- REG N/A
- Revenue Next Year
- ITCI $58.53
- REG $4.21
- P/E Ratio
- ITCI N/A
- REG $34.12
- Revenue Growth
- ITCI 46.62
- REG 9.74
- 52 Week Low
- ITCI $63.30
- REG $56.51
- 52 Week High
- ITCI $131.37
- REG $78.18
- Technical
- Relative Strength Index (RSI)
- ITCI 85.33
- REG 34.77
- Support Level
- ITCI $131.19
- REG $72.78
- Resistance Level
- ITCI $131.37
- REG $75.23
- Average True Range (ATR)
- ITCI 0.26
- REG 1.73
- MACD
- ITCI -0.55
- REG -0.59
- Stochastic Oscillator
- ITCI 99.70
- REG 3.47
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
About REG Regency Centers Corporation
Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 483 properties, which includes over 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.